XLO
Xilio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.00
−0.22%Margins
Gross margin
99.5%
EBITDA margin
-32.0%
EBIT margin
-48.9%
Net margin
-34.1%
FCF margin
-95.6%
-30.2%
Return on equity
-14.2%
Return on assets
-39.9%
Return on invested capital
0.40x
Asset turnover
-$60.6M
Cash from operations
$21
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026